A New Dawn of

Cancer & Viral Disease

Treatment and
Brain Protection

Preliminary Prospectus by
Hypermed
a Biomedical Technology Company
In La Jolla , California
www.hypermed.us
 Hypermed, Inc
A biomedical technology company in La Jolla, California, with U.S.
patented (US patent number 6669661) and patent-pending devices
and technology to achieve 4 product and service lines:

1. Hyperthermia technology to treat cancers and infections

2. Hypothermia Cool-Head Device to save injured or hypoxic brains
3. Advanced Ultra-Violet Germicidal Device to prevent hospital-
acquired infections and spread of epidemics
4. O.A.S.I.S. protocol to stop opiate addiction instantly and safely
without withdrawal
 Corporate Mission

Become global leader in the technology

and business of saving and extending
meaningful human lives.
 Science Team
Chief of Clinical Research: Dr. Matthew Cooper, MD FACS
former Clinical asst Professor, Dpt. of Surgery University of Nevada School of Medicine

Chief of Basic Science Research: Dr. Bing Mei Fu, Ph.D.

Assistant Professor, Department. of Mechanical Engineering, City College of New York

Chief of Medical and Animal Research: Dr. Kevin Murray, MD

former Chief of Cardiac Surgery, University of Nevada School of Medicine
 Management Team
President: Thomas C. Yee, MD MBA
former chief cardiac anesthesiology,
Univ. of Nevada School of Medicine
Vice President: Dr. Jason Yee, Ph.D.
Electrical Engineering Ph.D., Princeton University
Patent on Brain Protection
• “Method and Device for Central
Nervous System Protection During
Whole Body Hyperthermia or
Hypothermia”
• Includes novel use of pharmaceutical
agents and the use of new devices to
achieve safe profound whole-body
hyperthermia in order to treat cancer
patients and infectious disease
patients, or alternatively, to achieve
safe profound whole-body
hypothermia in order to preserve the
lives of critically ill patients.
• Invention can be viewed at
www.uspto.gov by searching for the
patent number 6669661
• View patent at
http://www.google.com/patents?
id=Co4NAAAAEBAJ&dq=6669661
 Market and Revenue Projections for Treating Cancers with
Hyperthermia

Approximately 500,000 persons

die annually in the US due to
cancer. Three times that number
die in affluent societies outside
US. Hyperthermia treatment
warrants compensations at least
similar to heart bypass surgeries
or to bone marrow transplant
procedures, costing between
$40,000 and $100,000. It is
reasonable to price the
Hyperthermia treatment at
$60,000. Assuming only 33% of
persons dying of cancer in
affluent societies (500,000
people) seek Hyperthermia
treatment, the annual revenue will
be thirty billion dollars.
($30,000,000,000)
 Market and Revenue Projection for Treating Viral Diseases

 In the US alone, there are more than

two million people with HIV
infection. Including all the affluent
societies in the world, more than five
million people have the same
infection. Tens of millions of people
are infected with Hepatitis B and C
that are otherwise incurable. Every
year, tens of thousands of people die
in the US from the flu. Around the
world, as the recent SARS epidemic
reminded us, influenza has the
potential of killing hundreds of
thousands of people every year.
 Assuming 300,000 seek the
Hyperthermia and Anti-Viral
Combination treatment, annual
revenue of eighteen billion dollars.
($18,000,000,000)
Market and Revenue Projection for Cool-Head hypothermia Device

• In the US over 1.5 million patients

suffer head trauma or anoxic brain
injury. Every unconscious patient
presenting to the emergency room
or trauma center optimally require
brain cooling and monitoring to
increase chance of recovery.
Global market is at least twice the
size of the US market.
• Priced at $2,000 per patient,
assuming only 50% of the eligible
1.5 million unconscious patients
get the brain-cooling treatment
offered by Cool-Head Device, the
annual revenue in the US alone is
$1,500,000,000.
Market and Revenue Projection for Advanced Ultra-
Violet Germicidal Device
• Hospital-acquired infection costs
the hospitals in the US an average
of $90,000 per case. There are
over 3,500 healthcare facilities
with over 150,000 cases of serious
hospital-acquired infections.
Global market is at least twice that
of US market.
• Priced at $3,000 per device
monthly rental rate, with over
35,000 facilities in the US and
additional 10,000 facilities outside
the U.S. requiring infection control
offered by the Advanced UVG
Device, at 4 devices per facility,
the annual rental revenue is
$500,000,000.
Market and Revenue Projection for OASIS protocol
(Opiate Addiction Safely and Instantly Stopped)

 In the US, 40,000 Americans die

from opiate overdose per year.
Currently Las Vegas Rapid Detox
Medical Clinic, owned by
Hypermed, Inc, charges $15,000
per procedure and performs 100
cases per year.
 Assuming 20,000 cases
performed per year, under license
to Hypermed, at a licensing fee of
$5,000 per case, the annual
revenue is projected to be
$100,000,000.
Financing and Timetable

Hypermed seeks investment of

between $10 to $50 million
USD to fund development
and production of the
patented method and devices
with 4 revenue streams

Revenue generation begins at

12 months after funding.
Funding Stage 1 (6 months)

Cool-Head Device
Manufacturing cost $300,000
Marketing cost $200,000

Adv UVG Device

Manufacturing cost $300,000
Marketing cost $200,000

Hyperthermia Device
Animal Study $1,000,000
(at Utah Artificial Heart Center)
---------------------------------------------------------
Stage 1 funding need $2,000,000

 
Funding Stage 2 (6 months)
Cool-Head Device
DEA app. cost $300,000
Manufacturing $300,000
Marketing $200,000
Adv. UVG Device
UL app cost $100,000
Manufacturing $300,000
Marketing $300,000

Hyperthermia Device
Animal Study $2,000,000
(at Utah Artificial Heart Center)
---------------------------------------------------------
Stage 2 total funding need
$3,500,000
 Funding Stage 3 (9 months)

Cool-Head Device
Manufacturing $1,200,000
Marketing $ 500,000 

Adv. UVG Device

Manufacturing $1,800,000
Marketing $ 500,000 

Hyperthermia Device
Clinical Trial $1,000,000
--------------------------------------------------------
Stage 3 total funding need
$5,000,000
 Funding Stage 4 (9 months)
Sales Revenue Starts
Cool-Head Device
Manufacturing $2,000,000
Marketing $1,000,000
Income from Sales ($2,500,000)
Net funding need $500,000
 
Adv. UVG Device
Manufacturing $2,000,000
Marketing $1,000,000
Income from Sales ($2,500,000)
Net funding need $500,000

Hyperthermia Device
Clinical Study $1,000,000
-----------------------------------------------------------
total funding need $2,000,000
Stage 5
(30 months after initial funding)
Annual Revenue

Cool-Head Device $200,000,000

Adv. UVG Device $100,000,000

Hyperthermia Tech$300,000,000
----------------------------------------
Stage 5 Projected Annual Revenue
$600,000,000

Company Valuation at twice annual

revenue: $1,200,000,000
 Stage 6
(60 months after initial funding)
Franchising and Licensing technology and
direct sales
Annual Revenue

Cool-Head Device $400,000,000

Adv. UVG Device $300,000,000

Hyperthermia Tech $800,000,000
--------------------------------------------------------------
Stage 6 Projected Annual Revenue
$1,500,000,000

Company valuation at twice annual revenue

$3,000,000,000
 S.W.O.T. Analysis
(Strength, Weakness, Opportunity, Threat)

Strength:
(1) Novelty of the concept
(2) Patented technique (Patent already granted)
(3) Great potential demand for the medical
service
(4) Highly respected animal research facility and
staff
(5) International basis for human studies
(6) Short duration of animal and human studies
(7) Early start up of commercially viable clinics
 S.W.O.T. Analysis
Weakness :
(1) Insufficient Funding
(2) Knowledge gap between lay person’s grasp of
basic science in this field and the breakthrough
at hand
(3) Experience gap between the average investors’
prior exposure to tech and biomed start-ups
and the magnitude of Hypermed’’s prospects
 S.W.O.T. Analysis
Opportunity
(1) Exclusive Cure of Cancer
(2) Exclusive Cure of viral diseases
(3) Life-extension hypothermia hibernation
(4) Patented exclusive technology can
dominate world market
 S.W.O.T. Analysis
Threat:
(1) Industrial Espionage
(2) Weak protection of intellectual rights in
countries in Asia
(3) Future competing technologies
 Conclusion & Vision
 This is a new technology company that owns
patented key technology in the arena of cancer
treatment, infection control, and brain protection.

 With an investment of between 10 to 50 million USD,

investors can own equity of a company that has
potential of billion Dollar annual revenue in 5 years.
United States Patent 6669661
 Granted to Dr. Thomas C. Yee
assigned by Dr. Yee to Hypermed

 “Method and device for central nervous system

protection during whole body hyperthermia or
hypothermia”

 View patent at:

http://www.google.com/patents?
id=Co4NAAAAEBAJ&dq=6669661
Background of the Invention
 The normal body temperature in a human
ranges between 36.1.degree C. and
37.2.degree C. An increase in body temperature
is a normal response to a bacterial or viral
infection.

 Cancer cells, HIV, and hepatitis virus cannot

survive extreme temperatures.

 To take advantage of this susceptibility to

temperature extremes, it is a well accepted
medical practice to induce single limb
hyperthermia to treat cancer isolated in limbs.

 Whole Body Hyperthermia can cause serious

side effects such as increased acidity in the
blood and neurological damage.
Purpose of the Invention as Applied
to Hypothermia (project 2)
 Sometimes it is desirable to intentionally induce
hypothermia for treatment purposes. For example, during
cardiac surgery, the body temperature may be reduced to
between 18 degrees. C. and 20 degrees. C. to allow
complete circulatory arrest. However, so far, hypothermia
is usually limited to less than sixty minutes to prevent
neurological damage.

 Hypothermia with appropriate neurological protection, as

in this patented invention, may provide safe hibernation
preservation of humans
Application of the Patented
Invention

 Therefore there is a need for a method

and device for raising the body
temperature above 45 degree C or
lowering the body temperature below 20
degree C for extended periods of time to
allow medical treatment without risking
neurological damage.
Patent Abstract
 A method and device for intentionally inducing whole-body
hyperthermia or hypothermia in a patient for medical treatment
while protecting the central nervous system from damage

 A tub for immersing the patient's body in a solution with a

temperature greater than or less than normal body temperature
to thereby increase or decrease the patient's body temperature.

 The patient's cerebral spinal fluid is circulated and maintained at

temperatures less drastically altered from normal temperatures
by a pump and a heater and cooler connected to the patient's
spine through catheters.

 The patient's central nervous system blood is separated from

the rest of the circulatory system and circulated and maintained
at temperatures less drastically altered from normal
temperatures by pumps and a heater and cooler. The remaining
blood in the patient's body is circulated and temperature
controlled through pumps and a heater and cooler.
Sites of Proposed Animal
Research

UCSD Animal Research

Facility
University of California, San Diego
La Jolla, California

Utah Artificial Heart Center

Salk Lake City, Utah
Development site of the Jarvik Artificial Heart
Supporting Scientific Studies:
Medical Journal: Annals of Oncology. 2002 Aug;13(8):1173-84.
Heating the patient: a promising approach?
van der Zee J.
Erasmus Medical Center-Daniel den Hoed Cancer Center, Department of
Radiation Oncology, Hyperthermia Unit, Rotterdam, The Netherlands

• The effects of both radiotherapy and many drugs are enhanced at an

increased temperature

• These findings justify using hyperthermia as part of standard treatment in

tumor sites for which its efficacy has been proven and, furthermore, to
initiate new studies with other tumors. Hyperthermia is certainly a
promising approach and deserves more attention than it has received until
now.
Medical Journal: Perfusion. 2002 Jul;17(4):279-90.
Whole-body hyperthermia: a review of
theory, design and application.

Vertree RA, Leeth A, Girouard M, Roach JD, Zwischenberger JB.

Department of Surgery,
The University of Texas Medical Branch, Galveston

• All patients were safely heated to 42 or 42.5 degrees C for 2 h and

survived the 30-day study period

• Hyperthermia has been used successfully to treat isolated neoplastic

lesions of the head and neck, regional tumors such as melanoma of
the limb, and is under investigation as either an adjunct to, or
therapy for, locally disseminated and systemic diseases
Critical Review of Oncology and Hematology. 2002
Jul;43(1):33-56.
The cellular and molecular basis of hyperthermia.

Hildebrandt B, Wust P, Ahlers O, Dieing A,

Sreenivasa G, Kerner T, Felix R,
Medical Clinic, Department of Hematology and Oncology,
Charite Medical School, Humboldt-University, Campus
Virchow Clinic, D-13344 Berlin, Germany.

An improvement of both local control and survival rates

have been demonstrated by adding local/regional
hyperthermia to radiotherapy in patients with locally
advanced or recurrent superficial and pelvic tumors
Surgery. 2002 Jan;131(1 Suppl):S121-7.
Hyperthermia for rectal cancer.

Ohno S, Sumiyoshi Y, Mori M, Sugimachi K.

Department of Breast Surgery, National Kyushu Cancer Center, Fukuoka,

Japan.

Hyperthermia combined with radiation or chemotherapy demonstrates great

promise for the treatment of patients with carcinoma of the rectum.
European Journal of Cancer. 2001 Jul;37(11):1429-34.

Enhancement of the therapeutic outcome of radio-

immunotherapy by combination with whole-body mild
hyperthermia.

Saga T, Sakahara H, Nakamoto Y, Sato N, Ishimori T, Mamede M,

Kobayashi H, Masunaga S, Sasai K, Kuroki M, Konishi J.

Department of Nuclear Medicine and Diagnostic Imaging, Graduate School

of Medicine, Kyoto, Japan.

The addition of whole-body mild hyperthermia significantly

enhanced the therapeutic effect of radio-immunotherapy by
increasing the radiosensitivity of the tumor.
International Journal of Hyperthermia. 2003 Jul-Aug;19(4):444-60.

Heat- and 4-hydroperoxy-ifosfamide-induced apoptosis in B cell

precursor leukaemias.

Mauz-Korholz C, Dietzsch S, Banning U, Trobs RB,

Korholz D.
Department of Pediatrics, University of Leipzig Medical
Center, Oststr 21-25, D-04317 Leipzig, Germany

• Application of hyperthermia enhances efficacy of

certain anti-neoplastic drugs such as ifosfamide

• whole body thermochemotherapy could be

considered as a treatment option in relapsed
leukaemic patients.
Cancer Immunology and Immunotherapy. 2002 Dec;51(11-12):603-13.

41.8 degrees C whole body hyperthermia as an adjunct to

chemotherapy induces prolonged T cell activation in patients with
various malignant diseases.

Atanackovic D, Nierhaus A, Neumeier M, Hossfeld DK, Hegewisch-

Becker S Department of Oncology and Hematology, University Clinic
Eppendorf, Hamburg, Germany

• This the first study to provide evidence for prolonged WBH-CT-

induced activation of human T cells.

• Whole body hyperthermia (WBH) has been used as an adjunct to

radio-/chemotherapy in patients with various malignant diseases
US National Cancer Institute Info
 The Cool-Head Device

Project 3

12/08/2021 38
 Vision Statement
 New Device capable of saving brains in
distress and offering viable brain life
extension in critically ill patients

12/08/2021 39
 Goal and Objective

 Incorporating Hydrogel, Rapid cooling

circulation covering head, neck, chest,
back, armpits, groins, abdomen skin
areas. Monitoring with Somanetics, BIS
EEG and nasopharyngeal temp probes.
 Seeking partners in the manufacturing and
marketing of Cool-Head device

12/08/2021 40
 Today’s Situation
 Brain death after 4 minutes of cardiac
arrest or respiratory arrest
 Emergency, trauma, ICU patients suffering
brain death

12/08/2021 41
 How Did We Get Here?
 Not Dead Till Warm and Dead
 Original assumptions that are no longer
valid: Heart arrests always lead to
immediate onset of brain death

12/08/2021 42
 Available Options
 Cool the brain rapidly or face brain-
damaged survivor
 Nothing more expensive to healthcare
system than a brain-damaged survivor of
cardiac arrest
 Use Cool-Head to increase brain survival
in cardiac/pulmonary arrest, head trauma,
stroke, shock patients
12/08/2021 43
 Next Steps
 Manufacture the Cool-Head based on
prototype
 Build sales network or partner with
distributors
 Market it to all EMT, OR and ICU

12/08/2021 44
 Contact

Hypermed
5440 La Jolla Blvd, Suite 207, La Jolla, CA 92037
www.hypermed.us
drthomasyee@gmail.com
TEL: (702) 813-3888